Correspondence 0001628280-24-050972 from Neurogene Inc. (NGNE)
Neurogene Inc.
Date: Dec. 12, 2024 · CIK: 0001404644 · Accession: 0001628280-24-050972
AI Filing Summary & Sentiment
File numbers found in text: 333-283561
Show Raw Text
CORRESP 1 filename1.htm Document December 12, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tamika Sheppard Re: Neurogene Inc. Registration Statement on Form S-1 Filed December 2, 2024 File No. 333-283561 To Whom it May Concern: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Neurogene Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:01 p.m., Eastern Time, on December 16, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631. Very truly yours, NEUROGENE INC. By: /s/ Donna Cochener Name: Donna Cochener Title: Senior Vice President, General Counsel cc: Rachel McMinn, Neurogene Inc. Christine Mikail, Neurogene Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP